Citigroup has recently initiated Viking Therapeutics Inc (VKTX) stock to Neutral rating, as announced on February 7, 2025, according to Finviz. Earlier, on December 2, 2024, Piper Sandler had initiated the stock to Overweight. B. Riley Securities also initiated Buy rating with a price target of $109. Additionally, H.C. Wainwright reiterated Buy rating on November 4, 2024, with a target price of $102. JP Morgan analysts, in their report published on September 11, 2024, also initiated Overweight rating and set a price target of $80 for Viking Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Viking Therapeutics Inc (VKTX) Stock Trading Recap
On Monday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $30.17 which represents a decrease of $-2.39 or -7.34% from the prior close of $32.56. The stock opened at $32.74 and touched a low of $29.91 during the day, reaching a high of $32.74. The volume of shares traded was 5.40 million exceeding the average volume of 4.00 million.
Sponsored
VKTX Stock Performance and Moving Averages
In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -4.28% over the last five trades and -25.69% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -45.90%, and it has plunged by -54.20% in the previous three months. Currently, VKTX is trading at -9.73%, -25.98%, and -46.35% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, VKTX, a Healthcare sector stock, is trading -69.65% below its 52-week high but remains 19.06% above its 52-week low. The Average True Range (ATR) (14 days) of 2.36 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Viking Therapeutics Inc’s Profitability and Valuation Ratios
Viking Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -45.90%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Viking Therapeutics Inc’s market capitalization stands at $3.36 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 3.82, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.66% of Viking Therapeutics Inc (VKTX)’s shares, while financial institutions hold 73.24%.
Notable insider trades include Lian Brian, President & CEO at Viking Therapeutics Inc (VKTX), who sold 194490 shares on Jan 06 ’25, at $42.75 each, totaling $8.31 million. On Jan 06 ’25, Mancini Marianna, Chief Operating Officer, sold 54215 shares for $42.75 each, amounting to $2.32 million. Additionally, on Jan 06 ’25, ZANTE GREG sold 50309 shares at $42.75 each, generating $2.15 million.
